These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 4724016)

  • 21. Synthesis and hypolipidaemic evaluation of a series of alpha-asarone analogues related to clofibrate in mice.
    Labarrios F; Garduño L; Vidal MR; Garcia R; Salazar M; Martinez E; Diaz F; Chamorro G; Tamariz J
    J Pharm Pharmacol; 1999 Jan; 51(1):1-7. PubMed ID: 10197410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and antilipidemic properties of cis-7-chloro-3a, 8b-dihydro-3a-methylfuro[3,4-b]benzofuran-3(1H)-one, a tricyclic clofibrate related lactone having a structural resemblance to mevalonolactone.
    Witiak DT; Kuwano E; Feller DR; Baldwin JR; Newman HA; Sankrappa SK
    J Med Chem; 1976 Oct; 19(10):1214-20. PubMed ID: 994152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of colestipol resin and of colestipol plus clofibrate on the turnover of plasma cholesterol in man.
    Goodman DS; Noble RP; Dell RB
    J Clin Invest; 1973 Oct; 52(10):2646-55. PubMed ID: 4729058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hypolipidemic activity of substances structurally close to penphenone in rats and mice].
    Polikarpova LI; Reznik SE; Ryzhenkov VV; Khechinashvili GG; Petrova LA
    Vopr Med Khim; 1978; 24(6):835-9. PubMed ID: 216145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative study of a new drug MK 185 with clofibrate in the treatment of hyperlipidaemias.
    Jepson EM; Small E; Grayson MF; Bance G; Billimoria JD
    Atherosclerosis; 1972; 16(1):9-14. PubMed ID: 4341723
    [No Abstract]   [Full Text] [Related]  

  • 26. Studies on hypolipidemic agents. III. Comparison of the hypolipidemic properties of 5-tridecylpyrazole-3-carboxylic acid and clofibrate.
    Seki K; Fukuda M; Isegawa J; Ohki M
    Chem Pharm Bull (Tokyo); 1984 Oct; 32(10):4103-9. PubMed ID: 6529804
    [No Abstract]   [Full Text] [Related]  

  • 27. Lentysine: a new hypolipidemic agent from a mushroom.
    Rokujo T; Kikuchi H; Tensho A; Tsukitani Y; Takenawa T; Yoshida K; Kamiya T
    Life Sci; 1970 Apr; 9(7):379-85. PubMed ID: 5463059
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of hypertriglyceridemia with tibric acid and clofibrate. Cross-over studies, effects on lipoproteins and absence of post-drug rebound.
    Smith FR; Noble RP; Goodman DS
    Atherosclerosis; 1978 Mar; 29(3):345-54. PubMed ID: 666884
    [No Abstract]   [Full Text] [Related]  

  • 29. The additive effects of clofibrate and probucol (DH-581) on rat serum cholesterol.
    Duncan CH; Best MM
    Atherosclerosis; 1973; 17(2):161-6. PubMed ID: 4709117
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of niceritrol (pentaerythritoltetranicotinate) and clofibrate upon hyperlipemia and atherosclerosis induced in rabbits by cholesterol-free semisynthetic diets.
    Brattsand R
    Atherosclerosis; 1974; 20(3):453-67. PubMed ID: 4373017
    [No Abstract]   [Full Text] [Related]  

  • 31. Thiomorpholine Derivatives with Hypolipidemic and Antioxidant Activity.
    Tooulia KK; Theodosis-Nobelos P; Rekka EA
    Arch Pharm (Weinheim); 2015 Sep; 348(9):629-34. PubMed ID: 26191791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Laboratory studies of 1-methyl-4-piperidyl bis(p-chlorophenoxy) acetate (SaH 42-348)--a new hypolipidemic agent.
    Timms AR; Kelly LA; Ho RS; Trapold JH
    Biochem Pharmacol; 1969 Aug; 18(8):1861-71. PubMed ID: 5811622
    [No Abstract]   [Full Text] [Related]  

  • 33. Fundamental studies on physiological and pharmacological actions of L-ascorbate 2-sulfate. I. On the hypolipidemic effects.
    Hayashi E; Yamada J; Kunitomo M; Terada M; Tomita T; Kinoshita
    J Nutr Sci Vitaminol (Tokyo); 1976; 22(3):201-8. PubMed ID: 966076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological profile of BR-931, a new hypolipidemic agent that increases high-density lipoproteins.
    Sirtori CR; Gomarasca P; D'Atri G; Cerutti S; Tronconi G; Scolastico C
    Atherosclerosis; 1978 May; 30(1):45-56. PubMed ID: 209796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The hypocholesterolemic action of eritadenine in the rat.
    Takashima K; Izumi K; Iwai H; Takeyama S
    Atherosclerosis; 1973; 17(3):491-502. PubMed ID: 4736648
    [No Abstract]   [Full Text] [Related]  

  • 36. Change of lipoprotein pattern by clofibrate in hyperglyceridaemia and mixed hyperlipidaemia.
    Miettinen TA; Penttilä IM; Lampainen E
    Acta Med Scand; 1972 Sep; 192(3):177-82. PubMed ID: 4341290
    [No Abstract]   [Full Text] [Related]  

  • 37. [Serum lipoproteins and antilipemic drugs related to clofibrate. Their in vitro interaction].
    Beaumont JL; Dachet C
    Atherosclerosis; 1973; 17(3):419-33. PubMed ID: 4351719
    [No Abstract]   [Full Text] [Related]  

  • 38. Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
    Shi GQ; Dropinski JF; Zhang Y; Santini C; Sahoo SP; Berger JP; Macnaul KL; Zhou G; Agrawal A; Alvaro R; Cai TQ; Hernandez M; Wright SD; Moller DE; Heck JV; Meinke PT
    J Med Chem; 2005 Aug; 48(17):5589-99. PubMed ID: 16107159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 6-Chlorochroman-2-carboxylic acids. Synthesis and biological evaluation as antagonists for cholesterol biosynthesis and lipolysis in vitro.
    Witiak DT; Stratford ES; Nazareth R; Wagner G; Feller DR
    J Med Chem; 1971 Aug; 14(8):758-66. PubMed ID: 5114072
    [No Abstract]   [Full Text] [Related]  

  • 40. Hypolipidemic effect of ethyl all-cis-5,8,11,14,17-eicosapentaenoate (EPA-E) in rats.
    Mizuguchi K; Yano T; Kojima M; Tanaka Y; Ishibashi M; Masada A; Sato M; Mizota M; Fukutake K; Saito Y
    Jpn J Pharmacol; 1992 Jul; 59(3):307-12. PubMed ID: 1434127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.